Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals Summit

It is a busy month for nuclear medicine meetings. If you are Munich for the Targeted Radiopharmaceuticals Summit be sure not too miss insights provided by our CEO Greg Mullen, PhD, FRSC in his talk entitled “Novel Targets in Radiopharmaceuticals” on Thursday 13th June at 12pm.